Meeting
2023 ASCO Annual Meeting
Phase 1 dose escalation study of SL-172154 (SIRPα-Fc-CD40L) in platinum-resistant ovarian cancer.
Authors
Nehal J. Lakhani
START Midwest, Grand Rapids, MI
Nehal J. Lakhani , Daphne B. Stewart , Debra L. Richardson , Lauren E. Dockery , Linda Van Le , Justin A Call , Fatima A. Rangwala , Anya Scholl , Guanfang Wang , Bo Ma , Simon Metenou , Louis Gonzalez , Arundathy Pandite , Erika P. Hamilton
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT04406623
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5544)
DOI
10.1200/JCO.2023.41.16_suppl.5544
Abstract #
5544
Poster Bd #
239
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer.
First Author: Stephanie Gaillard
Poster
2023 ASCO Annual Meeting
Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors.
First Author: Anwaar Saeed
Poster
2022 ASCO Annual Meeting
Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting multifunctional immune-recruitment protein, in patients with advanced solid tumors.
First Author: Jason J. Luke
Poster
2022 ASCO Annual Meeting
Preliminary data from an ongoing phase 1 dose-escalation study of CCX559, an orally administered small molecule PD-L1 inhibitor, in patients with advanced solid tumors.
First Author: Gonzalo Tapia